Laurion Capital Management LP boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 837.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 119,944 shares of the medical equipment provider’s stock after purchasing an additional 107,144 shares during the period. Laurion Capital Management LP’s holdings in Hologic were worth $5,443,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Stratos Wealth Partners LTD. lifted its stake in Hologic by 0.6% during the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after purchasing an additional 30 shares during the period. Cleararc Capital Inc. lifted its stake in Hologic by 1.1% during the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after purchasing an additional 77 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Hologic by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after purchasing an additional 85 shares during the period. Compton Capital Management Inc. RI lifted its stake in Hologic by 0.6% during the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after purchasing an additional 100 shares during the period. Finally, Symphony Asset Management LLC lifted its stake in Hologic by 0.4% during the second quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock worth $1,271,000 after purchasing an additional 108 shares during the period. Hedge funds and other institutional investors own 96.39% of the company’s stock.

A number of research analysts have commented on the stock. Jefferies Group LLC restated a “buy” rating and set a $49.00 price target on shares of Hologic in a research note on Wednesday, June 28th. Bank of America Corporation reiterated a “neutral” rating and issued a $48.00 target price (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Finally, BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. Hologic currently has an average rating of “Buy” and an average target price of $48.64.

In other news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72. Following the sale, the director now owns 23,810 shares of the company’s stock, valued at $1,078,116.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,594 shares of company stock valued at $1,168,871. 0.79% of the stock is currently owned by corporate insiders.

Hologic, Inc. (NASDAQ HOLX) traded down 0.05% during mid-day trading on Friday, reaching $37.72. 3,344,455 shares of the company’s stock were exchanged. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a market cap of $10.58 billion, a price-to-earnings ratio of 14.05 and a beta of 0.92. The stock has a 50-day moving average of $38.90 and a 200-day moving average of $42.58.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the company posted $0.51 earnings per share. Hologic’s revenue for the quarter was up 12.4% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Laurion Capital Management LP Has $5.44 Million Holdings in Hologic, Inc. (HOLX)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/17/laurion-capital-management-lp-has-5-44-million-holdings-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.